In conclusion, we demonstrated that a low‐dose of α‐Toc protects against NAFLD‐induced liver injury through an increase in CPT‐1 protein, which regulates mitochondrial lipid metabolism in the liver, whereas a high dose of α‐Toc suppresses these alterations. The gene discussed is CPT1A; the disease is metabolic dysfunction-associated steatotic liver disease.